Skip to content

The Impact of Saffron on Symptoms of Withdrawal Syndrome in Patients Undergoing Maintenance Treatment for Opioid Addiction in Sabzevar Parish in 2017

The Impact of Saffron on Symptoms of Withdrawal Syndrome in Patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017040433202N1
Enrollment
44
Registered
2017-05-15
Start date
2017-03-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Addiction. Mental and behavioural disorders due to psychoactive substance use

Interventions

Intervention 1: Intervention group: week 5 mg and 30 mg doses of methadone little saffron in the beginning of the study, the patient is given a survey carried out for 8 weeks the patient's symptom. In
Treatment - Drugs
Placebo
Intervention group: week 5 mg and 30 mg doses of methadone little saffron in the beginning of the study, the patient is given a survey carried out for 8 weeks the patient's symptom
Control: instead of saffron capsules to patients given placebo capsules self

Sponsors

Sabzevar University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion Criteria: in methadone maintenance phase stability; any one underlying disease; Consent to inclusion are injection molded. Exclusion Criteria: have underlying medical condition; Lack of personal satisfaction.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Rinoreh. Timepoint: Every week untill two months. Method of measurement: Self-reported.;Miyalgia. Timepoint: Every week untill two months. Method of measurement: Self-reported.;Loss of appetite. Timepoint: Every week untill two months. Method of measurement: Self-reported.;Temptation. Timepoint: Every week untill two months. Method of measurement: Self-reported.;Diarriah. Timepoint: Every week untill two months. Method of measurement: Self-reported.;Anxiety. Timepoint: Every week untill two months. Method of measurement: Self-reported.

Countries

Iran (Islamic Republic of)

Contacts

Public Contact??Atefeh Asadi

Medical Director of the lab

a.asadi.mm.1384@gmail.com+98 51 4422 9180

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026